- Home
- PLAY vs NUVB Comparison
PLAY vs NUVB Comparison
Compare PLAY & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLAY
- NUVB
- Stock Information
- Founded
- PLAY 1982
- NUVB 2018
- Country
- PLAY United States
- NUVB United States
- Employees
- PLAY N/A
- NUVB N/A
- Industry
- PLAY Restaurants
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- PLAY Consumer Discretionary
- NUVB Health Care
- Exchange
- PLAY Nasdaq
- NUVB Nasdaq
- Market Cap
- PLAY 678.9M
- NUVB 679.9M
- IPO Year
- PLAY 1995
- NUVB N/A
- Fundamental
- Price
- PLAY $22.26
- NUVB $2.16
- Analyst Decision
- PLAY Buy
- NUVB Strong Buy
- Analyst Count
- PLAY 6
- NUVB 5
- Target Price
- PLAY $27.00
- NUVB $8.20
- AVG Volume (30 Days)
- PLAY 1.1M
- NUVB 3.1M
- Earning Date
- PLAY 06-11-2025
- NUVB 05-07-2025
- Dividend Yield
- PLAY N/A
- NUVB N/A
- EPS Growth
- PLAY N/A
- NUVB N/A
- EPS
- PLAY 1.46
- NUVB N/A
- Revenue
- PLAY $2,132,700,000.00
- NUVB $10,957,000.00
- Revenue This Year
- PLAY $3.48
- NUVB $75.73
- Revenue Next Year
- PLAY $5.75
- NUVB $440.21
- P/E Ratio
- PLAY $15.30
- NUVB N/A
- Revenue Growth
- PLAY N/A
- NUVB N/A
- 52 Week Low
- PLAY $15.08
- NUVB $1.54
- 52 Week High
- PLAY $57.10
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- PLAY 63.12
- NUVB 53.36
- Support Level
- PLAY $19.85
- NUVB $1.98
- Resistance Level
- PLAY $22.60
- NUVB $2.25
- Average True Range (ATR)
- PLAY 1.04
- NUVB 0.16
- MACD
- PLAY 0.31
- NUVB -0.01
- Stochastic Oscillator
- PLAY 91.27
- NUVB 32.14
About PLAY Dave & Buster's Entertainment Inc.
Dave & Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).